Skip to main content
    B

    Biofrontera Inc (BFRI)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.85
    +0.02 (+2.06%)

    Market Cap: $13.25M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(9/20)
    Avg Surprise
    -60.22%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.11 - $-0.11
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.110.0%
    60d ago$-0.110.0%
    30d ago$-0.110.0%
    7d ago$-0.110.0%
    Current$-0.11
    Revenue Consensus
    $8M
    Range$8M - $9M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.02
    Range$0.02 - $0.02
    1 analysts
    Revenue Consensus
    $18M
    Range$18M - $18M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.02---
    Sep 26EST
    		-$-0.11---
    Jun 26
    Reported Aug 13
    		$-0.05N/A+70.59%Beat+91.2%
    Mar 26
    Reported May 14
    		$-0.41$-0.05-720.00%Miss+12.8%
    Dec 25
    Reported Mar 19
    		$0.50$0.10+400.00%Beat+315.5%
    Sep 25
    Reported Nov 12
    		$-0.57$-0.56-1.79%Miss+29.6%
    Jun 25
    Reported Aug 13
    		$-0.57$-0.39-46.15%Miss+47.2%
    Mar 25
    Reported May 15
    		$-0.47$-0.14-235.71%Miss+83.7%
    Dec 24
    Reported Mar 21
    		$-0.23$-0.07-231.43%Miss+65.9%
    Sep 24
    Reported Nov 13
    		$-0.81$-0.94+13.83%Beat+74.4%
    Jun 24
    Reported Aug 14
    		$-1.08$-0.35-208.57%Miss+82.2%
    Mar 24
    Reported May 15
    		$-2.88$-1.17-146.15%Miss+10.6%
    Dec 23
    Reported Mar 15
    		$-0.68$-0.85+20.00%Beat-385.7%
    Sep 23
    Reported Nov 9
    		$-3.16$-3.34+5.39%Beat+39.7%
    Jun 23
    Reported Aug 11
    		$-6.07$-4.08-48.77%Miss+29.7%
    Mar 23
    Reported May 12
    		$-3.22$-3.40+5.29%Beat+47.3%
    Dec 22
    Reported Mar 7
    		$-0.14$-0.11-27.27%Miss+6.7%
    Sep 22
    Reported Nov 14
    		$-5.24$-5.80+9.66%Beat+45.8%
    Jun 22
    Reported Aug 12
    		$-8.63$-6.80-26.91%Miss-1592.2%
    Mar 22
    Reported Apr 8
    		$-6.11$-3.60-69.72%Miss-
    Dec 21
    Reported Dec 31
    		$-0.15$-0.18+16.67%Beat-
    Sep 21
    Reported Nov 1
    		$-9.66$-11.60+16.72%Beat-
    Jun 21
    Reported Jul 6
    		$-0.51$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.60EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-13.80%Operating Margin-4.37%
    ROE-988.00%ROIC-55.35%
    Financial Health
    Debt/Equity0.78xInterest CoverageN/A
    Current Ratio1.18xQuick Ratio1.08x
    Trading Statistics
    Beta0.88Avg Volume370.72K
    52-Week High$1.6652-Week Low$0.56

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.92
    SMA 20$1.03
    SMA 50$1.26
    SMA 200$1.03
    EMA 10$0.93
    EMA 20$1.02
    EMA 50$1.14
    EMA 200$1.07

    MACD

    Line: -0.12Signal: -0.11Hist: -0.01

    ADX

    ADX: 32.7+DI: 14.9-DI: 31.8

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$1.01

    Bollinger Bands

    Upper Band$1.31
    Lower Band$0.76
    %B Position5325%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    30.8

    Momentum Oscillators

    Stoch %K6.3
    Stoch %D11.5
    Williams %R-92.3
    ROC (10d)-18.5%
    Momentum-0.19
    CCI (20d)-110.0
    MFI (14d)24.9

    Volatility Measures

    ATR (14d)$0.09(10.5%)
    StdDev (20d)0.14
    Hist Vol81.0%(High)

    Volume Flow

    VWAP$0.85
    OBV-10.4M
    AD Line3.3M
    CMF (20d)-0.235

    Volume Metrics

    Avg Vol (20d)359.7K
    Vol Ratio0.8x
    VWMA (20d)$1.04

    Pivot Points

    R3$0.94
    R2$0.92
    R1$0.87
    Pivot Point$0.85
    S1$0.80
    S2$0.78
    S3$0.73

    Advanced Oscillators

    TSI-34.52
    Ultimate Osc34.0
    KST-308.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$12.00M$10.08M$17.10M$6.99M$9.03M$8.59M$12.56M$9.01M$7.84M$7.91M$10.59M$8.90M
    Cost of Revenue$2.41M$2.12M$3.01M$2.04M$2.64M$3.27M$5.27M$4.88M$4.34M$4.12M$5.37M$4.59M
    Gross Profit$9.59M$7.97M$14.09M$4.94M$6.39M$5.32M$7.29M$4.13M$3.50M$3.80M$5.23M$4.31M
    Operating Expenses$10.12M$12.29M$9.54M$11.22M$11.47M$9.87M$9.00M$9.10M$8.57M$9.26M$9.09M$8.93M
    R&D$448,000$900,000$788,000$854,000$870,000$1.21M$782,000$669,000$621,000$17,000$33,000$33,000
    SG&A$9.67M$11.00M$8.75M$10.37M$10.60M$8.66M$8.22M$8.43M$7.95M$9.25M$9.06M$8.69M
    Operating Income$-524,000$-4,320,000$4.56M$-6,278,000$-5,079,000$-4,547,000$-1,712,000$-4,960,000$-5,071,000$-5,467,000$-3,866,000$-4,620,000
    Interest Income$-127,000$-125,000$-121,000$-110,000$-113,000$-106,000$-41,000$6,000$-610,000$-1,404,000$-1,112,000$-2,354,000
    Interest Expense$57,000$432,000$0$0$224,000$0$0$0$0$316,000$-114,000$0
    Income Before Tax$-581,000$-4,752,000$5.64M$-6,643,000$-5,303,000$-4,204,000$-1,398,000$-5,666,000$-237,000$-10,436,000$3.52M$-6,341,000
    Income Tax Expense$23,000$0$-1,000$6,000$21,000$-1,000$-2,000$3,000$20,000$1,000$-6,000$1,000
    Net Income$-604,000$-4,752,000$5.64M$-6,649,000$-5,324,000$-4,203,000$-1,396,000$-5,669,000$-257,000$-10,437,000$3.53M$-6,342,000
    EBITDA$-258,000$-4,440,000$5.98M$-6,326,000$-4,968,000$-3,879,000$-1,136,000$-5,360,000$682,000$-8,409,000$4.81M$-3,736,000
    EBIT$-454,000$-4,627,000$5.76M$-6,533,000$-5,190,000$-4,098,000$-1,357,000$-5,672,000$373,000$-8,716,000$4.52M$-3,987,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BFRI

    Government Contracts

    Gov Obligations (TTM)
    $32000
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24826P0704Department of Veterans AffairsDepartment of Veterans Affairs$32000Apr 9, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Biofrontera submits application to expand Ameluz use for AKs

    Biofrontera Inc. has submitted a supplemental New Drug Application to the FDA to expand the approved use of its Ameluz topical gel for treating mild-to-moderate actinic keratoses. The application seeks to extend...

    Investing.com•10/8/26•Bullish

    Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

    Biofrontera Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for its Ameluz® (aminolevulinic acid hydrochloride) topical gel to treat mild-to-moderate actinic keratoses...

    The Manila Times•10/8/26•Bullish

    Biofrontera Submits sNDA to Expand Ameluz PDT for Actinic Keratoses Across the Body

    Biofrontera Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for Ameluz photodynamic therapy (PDT) to treat mild-to-moderate actinic keratoses (AKs) on the extremities...

    Dermatology Times•10/8/26•Bullish

    Biofrontera submits application to expand Ameluz use for AKs By Investing.com

    Biofrontera Inc. has submitted a supplemental New Drug Application to the FDA to expand the approved use of its Ameluz topical gel for treating mild-to-moderate actinic keratoses on the extremities, neck...

    Investing.com Canada•10/8/26•Bullish

    Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

    Biofrontera Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for its Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%...

    GlobeNewswire•10/8/26•Bullish

    BFRI Valuation and Fair Value

    P/E
    -1.6x
    Forward P/E
    13.0x
    P/B
    1.8x
    See GNG's fair value

    BFRI Profitability: Margins, ROIC and FCF

    Gross margin
    79.3%
    Operating margin
    -4.4%
    Net margin
    -13.8%
    ROIC
    -55.4%
    ROE
    -988.0%
    FCF margin
    -17.2%

    BFRI Competitors

    CompanyTicker
    Tvardi Therapeutics, Inc.TVRD
    Femasys IncFEMY
    Vyome Holdings, Inc.HIND
    GT Biopharma IncGTBP
    Citius Pharmaceuticals IncCTXR
    Anebulo Pharmaceuticals IncANEB
    SINTX Technologies IncSINT
    Synlogic IncSYBX

    Sector: Healthcare

    BFRI Bull Case vs Bear Case

    Bull case

    • BFRI grew quarterly revenue 32.9% year over year.

    Bear case

    • BFRI has a -13.8% net profit margin.
    • BFRI beat EPS estimates in 37.5% of its last 8 reported quarters.

    BFRI Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -93.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.11
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About BFRI

    Does BFRI pay dividends?

    Biofrontera Inc (BFRI) does not currently pay a regular dividend.

    What is BFRI's market cap?

    Biofrontera Inc (BFRI) has a market capitalization of $13.25M with a current stock price of $0.85.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In